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BACKGROUND
The selective cardiac myosin activator omecamtiv mecarbil has been shown to im-
prove cardiac function in patients with heart failure with a reduced ejection fraction. 
Its effect on cardiovascular outcomes is unknown.
METHODS
We randomly assigned 8256 patients (inpatients and outpatients) with symptom-
atic chronic heart failure and an ejection fraction of 35% or less to receive 
omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 
50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The 
primary outcome was a composite of a first heart-failure event (hospitalization or 
urgent visit for heart failure) or death from cardiovascular causes.
RESULTS
During a median of 21.8 months, a primary-outcome event occurred in 1523 of 
4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 pa-
tients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval 
[CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients 
(19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 
0.92 to 1.11). There was no significant difference between groups in the change 
from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom 
score. At week 24, the change from baseline for the median N-terminal pro–B-type 
natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in 
the placebo group; the median cardiac troponin I level was 4 ng per liter higher. 
The frequency of cardiac ischemic and ventricular arrhythmia events was similar 
in the two groups.
CONCLUSIONS
Among patients with heart failure and a reduced ejection, those who received 
omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event 
or death from cardiovascular causes than those who received placebo. (Funded by 
Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT 
number, 2016 - 002299 - 28.)
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The defining characteristic of heart failure with a reduced ejection frac-tion is decreased systolic function leading 
to reduced cardiac output and increased filling 
pressures. To date, no medications that directly 
enhance systolic function have improved out-
comes.1 Cardiac myosin activators are a new class 
of myotropes2 that improve myocardial function 
by directly augmenting cardiac sarcomere func-
tion. Omecamtiv mecarbil,3,4 the first of this class, 
augments cardiac contractility by selectively bind-
ing to cardiac myosin,5 thus increasing the num-
ber of force generators (myosin heads) that can 
bind to the actin filament and initiate a power 
stroke at the start of systole. Short-term intrave-
nous administration of omecamtiv mecarbil im-
proved cardiac performance in early clinical 
studies.6-8
In patients with chronic heart failure with a 
reduced ejection fraction, the administration of 
omecamtiv mecarbil for 20 weeks increased the 
left ventricular systolic ejection time and stroke 
volume, decreased the left ventricular systolic and 
diastolic volumes (which suggested beneficial 
reverse cardiac remodeling), and reduced the 
plasma natriuretic peptide levels and heart rate.9 
On the basis of these findings, we designed and 
conducted the randomized, placebo-controlled, 
phase 3 Global Approach to Lowering Adverse 
Cardiac Outcomes through Improving Contractil-
ity in Heart Failure (GALACTIC-HF) trial to assess 
whether treatment with omecamtiv mecarbil in 
patients with heart failure who had a reduced 
ejection fraction would lower the risk of heart-
failure events and cardiovascular death.10,11
Me thods
Trial Design and Oversight
The executive committee designed and oversaw 
the conduct and analysis of the trial in collabo-
ration with the sponsors, Amgen, Cytokinetics, 
and Servier.10 The trial was conducted and reported 
in accordance with the protocol and the statisti-
cal analysis plan, which are available in the same 
document with the full text of this article at 
NEJM.org. The trial was approved by the regula-
tory agencies in the participating countries and 
by the institutional review board or ethics com-
mittee at each trial center. An independent data 
monitoring committee evaluated patient safety.
The executive committee and sponsors partici-
pated in the trial design and in the selection of 
participating centers and interpretation of the data; 
Amgen was responsible for site monitoring and 
for the collection, storage, and initial analyses 
of the data, evaluations that were replicated by 
an independent academic statistician (Table S1 
in the Supplementary Appendix, available at 
NEJM.org). The first author had unrestricted ac-
cess to the data and drafted the initial version of 
the manuscript, which was reviewed and edited 
by all the authors, who made the decision to 
submit the manuscript for publication. The ex-
ecutive committee vouches for the accuracy and 
completeness of the analyses and for the fidelity 
of the trial to the protocol.
Patients
Eligibility requirements included an age between 
18 and 85 years, along with New York Heart As-
sociation functional class II, III, or IV symptoms 
and a left ventricular ejection fraction of 35% or 
less. The patients were currently hospitalized for 
heart failure (inpatients) or had either made an 
urgent visit to the emergency department or been 
hospitalized for heart failure within 1 year be-
fore screening (outpatients). All the patients had 
an N-terminal pro–B-type natriuretic peptide 
(NT-proBNP) level of 400 pg per milliliter or 
more or a BNP level of 125 pg per milliliter or 
more; among the patients with atrial fibrillation 
or flutter, the cutoff NT-proBNP level was 1200 pg 
per milliliter or more and the cutoff BNP level 
was 375 pg per milliliter or more. Patients were 
required to receive pharmacologic and device 
therapy for heart failure in accordance with re-
gional clinical practice guidelines and with 
doses optimized according to the investigator’s 
judgment.
Key exclusion criteria were current hemody-
namic or clinical instability leading to the use of 
mechanical support or intravenous medication, 
a systolic blood pressure of less than 85 mm Hg, 
an estimated glomerular filtration rate (GFR) of 
less than 20 ml per minute per 1.73 m2 of body-
surface area, a recent acute coronary syndrome 
event or cardiovascular procedure (including a 
planned procedure), and other conditions that 
would adversely affect participation in the trial. 
A full description of the eligibility criteria has 
been published previously10 and is available in the 
Supplementary Appendix. All the patients provided 
written informed consent.
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Age — yr 64.5±11.3 64.5±11.4
Female sex — no. (%) 875 (21.2) 874 (21.3)
Race or ethnic group — no. (%)†
White 3196 (77.6) 3201 (77.8)
Asian 355 (8.6) 355 (8.6)
Black 285 (6.9) 277 (6.7)
Other 284 (6.9) 279 (6.8)
Geographic region — no. (%)
Eastern Europe or Russia 1344 (32.6) 1337 (32.5)
Western Europe, South Africa, or Australasia 961 (23.3) 960 (23.3)
Latin America 787 (19.1) 787 (19.1)
United States or Canada 693 (16.8) 693 (16.9)
Asia 335 (8.1) 335 (8.1)
Inpatient setting — no. (%) 1044 (25.3) 1040 (25.3)
Clinical features
Atrial fibrillation or flutter — no. (%) 1146 (27.8) 1099 (26.7)
Type 2 diabetes mellitus — no. (%) 1652 (40.1) 1657 (40.3)
Ischemic heart failure — no. (%) 2193 (53.2) 2222 (54.0)
Left ventricular ejection fraction — % 26.6±6.3 26.5±6.3
NYHA classification — no. (%)
II 2195 (53.3) 2173 (52.8)
III 1801 (43.7) 1815 (44.1)
IV 124 (3.0) 124 (3.0)
Median total symptom score on KCCQ (IQR)‡ 68.8 (49.0–87.5) 68.8 (49.0–87.5)
Outpatient 74.0 (54.2–90.6) 75.0 (56.3–91.7)
Inpatient 54.2 (34.4–72.9) 52.1 (31.3–69.8)
Systolic blood pressure — mm Hg 116.3±15.4 116.6±15.3
Heart rate — beats/min 72.4±12.2 72.3±12.1
Median NT-proBNP (IQR) — pg/ml 1977 (980–4061) 2025 (1000–4105)
Median cardiac troponin I (IQR) — ng/liter 27 (12–52) 27 (13–52)
Median eGFR (IQR) — ml/min/1.73m2 58.8 (44.3–74.3) 58.7 (43.8–73.7)
Heart-failure therapy — no. (%)
ACE inhibitor, ARB, or ARN inhibitor 3583 (87.0) 3576 (87.0)
ARN inhibitor 819 (19.9) 782 (19.0)
Beta-blocker 3881 (94.2) 3883 (94.4)
Mineralocorticoid-receptor antagonist 3199 (77.6) 3198 (77.8)
SGLT2 inhibitor 104 (2.5) 114 (2.8)
Cardiac-resynchronization therapy 592 (14.4) 566 (13.8)
Implantable cardioverter–defibrillator 1326 (32.2) 1288 (31.3)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Additional baseline character-
istics are provided in Tables S3 and S4 in the Supplementary Appendix. ACE denotes angiotensin-converting enzyme, 
ARB angiotensin-receptor blocker, ARN angiotensin receptor–neprilysin, eGFR estimated glomerular filtration rate, IQR 
interquartile range, NT-proBNP N-terminal pro–B-type natriuretic peptide, NYHA New York Heart Association, and 
SGLT2 sodium–glucose cotransporter 2.
†  Race or ethnic group was reported by the patients. The category of Other includes American Indian or Alaska Native, 
Native Hawaiian or other Pacific Islander, or multiple patient-identified races or ethnic groups.
‡  Scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) range from 0 to 100, with higher scores indicating a 
lower frequency and severity of symptoms.
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Trial Procedures
We randomly assigned patients in a 1:1 ratio to 
receive either oral omecamtiv mecarbil or placebo 
using an interactive Web-response or voice-response 
system and a sequestered, fixed randomization 
schedule, with balanced blocks within strata 
defined according to the randomization setting 
(inpatient or outpatient) and geographic region. 
The patients were assigned to receive omecamtiv 
mecarbil at a dose of 25 mg, 37.5 mg, or 50 mg 
twice daily on the basis of plasma levels of the 
drug, as described in the Supplementary Appen-
dix. All the patients and investigators were un-
aware of the plasma levels and the dispensed dose. 
Postrandomization assessments were performed 
at weeks 2, 4, 6, 8, 12, 24, 36, and 48 and every 
16 weeks thereafter (Fig. S1 and Table S2). The 
administration of omecamtiv mecarbil or place-
bo was temporarily suspended if the patient had 
clinical signs or symptoms consistent with acute 
myocardial infarction or ischemia.
Primary and Secondary Outcomes
The primary outcome was a composite of a heart-
failure event or cardiovascular death, whichever 
occurred first, in a time-to-event analysis. A heart-
failure event was defined as an urgent clinic 
visit, emergency department visit, or hospitaliza-
tion for subjectively and objectively worsening 
heart failure leading to treatment intensification 
beyond a change in oral diuretic therapy.12 Sec-
ondary outcomes were cardiovascular death, the 
change in the total symptom score on the Kan-
sas City Cardiomyopathy Questionnaire (KCCQ) 
from baseline to week 24 (on a scale of 0 to 100, 
with higher scores indicating a lower frequency 
and severity of symptoms), the first heart-failure 
hospitalization, and death from any cause. All 
deaths, heart-failure events, major cardiac isch-
emic events (myocardial infarction, hospitaliza-
tion for unstable angina, and coronary revascu-
larization), and strokes were adjudicated by an 
external clinical-events committee at the Duke 
Figure 1. Primary Composite Outcome.
The primary outcome was a composite of a heart-failure event or cardiovascular death, whichever occurred first. The cumulative inci-
dence of the primary composite outcome (Panel A) and death from cardiovascular causes (Panel B) was estimated with the use of the 
Kaplan–Meier method. Hazard ratios and 95% confidence intervals were estimated with the use of Cox regression models stratified ac-
cording to randomization location and geographic region, with the trial group as an explanatory variable. Analyses were performed in 
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Clinical Research Institute, whose members were 
unaware of trial group assignments and used 
standardized definitions. (Details are provided in 
the Supplementary Appendix.12)
Statistical Analysis
We determined that the enrollment of approxi-
mately 8000 patients would provide a power of 
90% to detect a hazard ratio of 0.80 for cardio-
vascular death in the group receiving omecamtiv 
mecarbil (Fig. S2). The trial was event driven with 
a target of approximately 1590 cardiovascular 
deaths. The overall type I error was 0.05 for two-
sided testing across primary and secondary out-
comes. Control for multiple comparisons was 
achieved by means of the following testing algo-
rithm: if the primary outcome met the P-value 
threshold of 0.05, the alpha error would be di-
vided unequally between cardiovascular death 
(96% of the overall alpha error, or 0.048) and the 
change from baseline to week 24 in the KCCQ 
total symptom score (4% of the overall alpha er-
ror, or 0.002).13 On the basis of a one-sided alpha 
level of 0.0005, a single interim efficacy analysis 
was conducted after approximately two thirds of 
the targeted number of cardiovascular deaths 
had occurred. Given the negligible effect of this 
interim analysis on the final alpha level, the full 
alpha error of 0.05 was used in the final analysis, 
consistent with the Haybittle–Peto approach.14,15
We performed the efficacy analysis in the full 
analysis set of the intention-to-treat population, 
Table 2. Primary and Secondary Cardiovascular Outcomes.*
Variable




Hazard Ratio or 
Difference 
(95% CI)† P Value





Primary composite outcome — no. (%)‡ 1523 (37.0) 24.2 1607 (39.1) 26.3 0.92 (0.86 to 0.99) 0.03
Cardiovascular death as first event 346 (8.4) 371 (9.0)
Hospitalization for heart failure as first 
event
1107 (26.9) 1133 (27.6)
Urgent outpatient visit for heart failure as 
first event
70 (1.7) 103 (2.5)
Secondary outcomes
Cardiovascular death — no. (%) 808 (19.6) 10.9 798 (19.4) 10.8 1.01 (0.92 to 1.11) 0.86§
Change in KCCQ total symptom score  
at wk 24
0.03§
Inpatients 23.7±0.7 NA 21.2±0.7 NA 2.5 (0.5 to 4.5)
Outpatients 5.8±0.3 NA 6.3±0.3 NA −0.5 (−1.4 to 0.5)
First hospitalization for heart failure —  
no. (%)
1142 (27.7) 18.0 1179 (28.7) 19.1 0.95 (0.87 to 1.03) NA
Death from any cause — no. (%) 1067 (25.9) 14.4 1065 (25.9) 14.4 1.00 (0.92 to 1.09) NA
Exploratory outcome
Heart-failure event — no. (%) 1177 (28.6) 18.7 1236 (30.1) 20.3 0.93 (0.86 to 1.00) NA
*  Plus–minus values are least-squares means ±SE. P values for efficacy outcomes are reported only for outcomes that were included in the 
hierarchical-testing strategy. NA denotes not applicable.
†  All listed values are hazard ratios except for the between-group differences in the changes in the total symptom score on the Kansas City 
Cardiomyopathy Questionnaire (KCCQ).
‡  The primary outcome was a composite of heart-failure events (hospitalization or unscheduled urgent clinic, office, or emergency depart-
ment visit resulting in intravenous therapy for heart failure) or death from cardiovascular causes.
§  The between-group difference in this category was not determined to be significant. After the determination of significance for the primary 
outcome, cardiovascular death was tested against an alpha of 0.048, and the change from baseline in the KCCQ total symptom score was 
tested against an alpha of 0.002 with a joint test for an effect among inpatients and outpatients. (Additional details about the statistical 
analysis are provided in the Supplementary Appendix.)
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which included all the patients who had under-
gone randomization except for 24 patients from 
a single site who were excluded on the basis of 
Good Clinical Practice violations. We evaluated 
time-to-event data using Kaplan–Meier estimates 
and Cox proportional-hazards models with base-
line hazards stratified according to the random-
ization setting (inpatient or outpatient) and geo-
graphic region and with the trial group and the 
baseline estimated GFR as covariates. The mean 
differences in the change in the KCCQ total symp-
tom score from baseline to week 24 were estimated 
with the use of mixed models fit within the ran-
domization setting, with each model containing 
fixed effects for the baseline total symptom 
score, geographic region, baseline estimated GFR, 
scheduled visit (week 12 or week 24), trial group, 
and the interaction between trial group and sched-
uled visit and an unstructured covariance matrix 
for repeated measures across visits. A joint omni-
bus F-test of a treatment difference within at least 
one subset of trial patients (inpatients or outpa-
tients) was used to test the treatment effect for 
the KCCQ total symptom score.
The prespecified safety analyses included se-
rious adverse events, adverse events associated 
with the discontinuation of omecamtiv mecarbil 
or placebo, and adverse events of interest (i.e., ven-
tricular arrhythmias leading to treatment and 
positively adjudicated major cardiac ischemic 
events that included myocardial infarction, hos-
pitalization for unstable angina, and coronary 
revascularization). The safety analyses were per-
formed in patients who had undergone random-
ization and received at least one dose of omecam-
tiv mecarbil or placebo, with the exclusion of the 
same 24 patients who had been excluded from 
the full analysis set. All analyses were performed 




From January 6, 2017, to July 9, 2019, a total of 
11,121 patients underwent screening at 945 sites 
in 35 countries. Of these patients, 8256 under-
went randomization. After 24 patients were ex-
cluded because of Good Clinical Practice viola-
tions, 4120 patients were assigned to receive 
omecamtiv mecarbil and 4112 to receive placebo 
(Fig. S3). The characteristics of the patients at base-
line were well balanced in the two trial groups 
(Table 1 and Tables S3 and S4).11 At week 12, 
among the patients who were assigned to receive 
omecamtiv mecarbil twice daily, 1192 patients 
(28.9%) were receiving the 25-mg dose, 559 (13.6%) 
the 37.5-mg dose, and 1961 (47.6%) the 50-mg 
dose; the remaining 408 patients (9.9%) were not 
included in this analysis owing to discontinua-
tion, missing study-visit data, or other reasons.
The overall median duration of follow-up was 
21.8 months (interquartile range, 15.4 to 28.6). 
A total of 41 patients in the omecamtiv mecarbil 
group and 50 patients in the placebo group dis-
continued participation before the end of the 
trial on August 7, 2020. At that time, 16 patients 
had unknown vital status.
Outcomes
The primary outcome of a first heart-failure 
event or death from cardiovascular causes oc-
curred in 1523 of 4120 patients (37.0%) in the 
omecamtiv mecarbil group and in 1607 of 4112 
patients (39.1%) in the placebo group (hazard 
ratio, 0.92; 95% confidence interval [CI], 0.86 to 
0.99; P = 0.03) (Fig. 1A and Table 2). The effect 
of omecamtiv mecarbil was generally consistent 
across most prespecified subgroups, with the 
exception of a possible interaction between trial 
group and ejection fraction at baseline (Fig. 2).
The secondary outcome of death from cardio-
vascular causes occurred in 808 patients (19.6%) 
in the omecamtiv mecarbil group and in 798 pa-
tients (19.4%) in the placebo group (hazard ratio, 
1.01; 95% CI, 0.92 to 1.11; P = 0.86) (Fig. 1B and 
Table 2). In the prespecified analysis of the 
Figure 2 (facing page). Primary Composite Outcome, 
According to Prespecified Subgroup.
Shown is the primary outcome of the trial, a composite 
of a heart-failure event or cardiovascular death, accord-
ing to baseline values in subgroups that were prespeci-
fied in the protocol. Patients with atrial fibrillation or 
flutter at screening were not included in the analysis of 
NT-proBNP at baseline. Race or ethnic group were re-
ported by the patients. ACE denotes angiotensin-con-
verting enzyme, ARB angiotensin-receptor blocker, 
ARN angiotensin receptor–neprilysin, BP blood pres-
sure, CRT cardiac-resynchronization therapy, eGFR esti-
mated glomerular filtration rate, ICD implantable car-
dioverter–defibrillator, LVEF left ventricular ejection 
fraction, MRA mineralocorticoid-receptor antagonist, 
NT-proBNP N-terminal pro–B-type natriuretic peptide, 
and NYHA New York Heart Association.
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change from baseline to week 24 in the KCCQ 
total symptom score according to randomization 
setting, the mean between-group difference in 
the change (omecamtiv mecarbil minus placebo) 
was 2.5 points (95% CI, 0.5 to 4.5) among inpa-
tients and −0.5 (−1.4 to 0.5) among outpatients 
(P = 0.03 by joint omnibus F-testing). The com-
bined P value for these comparisons did not meet 
the significance threshold of 0.002, according to 
the testing procedure for multiplicity control.






 (N = 4101)
Relative Risk  
or Difference 
(95% CI)†
Change from baseline in vital signs and laboratory measures
Systolic blood pressure — mm Hg
At wk 24 1.4±15.3 1.5±15.6 −0.1 (−0.9 to 0.6)
At wk 48 2.0±16.1 1.9±16.0 0.2 (−0.6 to 1.0)
Heart rate — beats/min
At wk 24 −2.1±12.6 −0.5±12.8 −1.6 (−2.2 to −1.0)
At wk 48 −2.0±13.1 −0.2±13.2 −1.8 (−2.4 to −1.1)
Potassium – mmol/liter
At wk 24 −0.01±0.57 −0.01±0.57 0.00 (−0.03 to 0.03)
At wk 48 −0.03±0.59 −0.02±0.58 −0.01 (−0.04 to 0.02)
Creatinine — mg/dl
At wk 24 0.03±0.33 0.02±0.32 0.01 (−0.01 to 0.02)
At wk 48 0.06±0.39 0.05±0.38 0.01 (−0.01 to 0.03)
Median NT-proBNP (IQR) — pg/ml‡
At wk 24 −251 (−1180 to 295) −180 (−915 to 441) 0.90 (0.86 to 0.94)
Median cardiac troponin I (IQR) — ng/liter
At wk 24 4 (−2 to 21) 0 (−9 to 8) 4 (3 to 5)
At wk 48 2 (−4 to 18) 0 (−9 to 8) 2 (1 to 3)
Safety outcomes — no. (%)§
Discontinuation because of adverse event 371 (9.0) 382 (9.3) 0.97 (0.85 to 1.11)
Serious adverse event 2373 (57.7) 2435 (59.4) 0.97 (0.94 to 1.01)
Adverse event of interest
Ventricular tachyarrhythmia 290 (7.1) 304 (7.4) 0.95 (0.82 to 1.11)
Torsades de pointes or QT prolongation 176 (4.3) 195 (4.8) 0.90 (0.74 to 1.10)
Serious adverse ventricular arrhythmia leading to treatment 119 (2.9) 127 (3.1) 0.93 (0.73 to 1.20)
Adjudicated major cardiac ischemic event 200 (4.9) 188 (4.6) 1.06 (0.87 to 1.29)
Myocardial infarction 122 (3.0) 118 (2.9) —
Hospitalization for unstable angina 25 (0.6) 12 (0.3) —
Coronary revascularization 115 (2.8) 117 (2.9) —
Adjudicated stroke 76 (1.8) 112 (2.7) 0.68 (0.51 to 0.91)
*  Plus–minus values are means ±SD. To convert the values for potassium to milligrams per deciliter, divide by 0.2558. To convert the values 
for creatinine to micromoles per liter, multiply by 88.4.
†  The data are reported as relative risk for all safety outcomes.
‡  For the NT-proBNP value, the between-group difference is the geometric mean ratio as determined by the exponentiation of the change 
from baseline in log-transformed values from a mixed model containing the log baseline value, geographic region, baseline eGFR, sched-
uled visit, trial group, and interaction of trial group with the scheduled visit.
§  The safety population included all patients who had undergone randomization and received at least one dose of omecamtiv mecarbil or pla-
cebo.
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A first hospitalization for heart failure oc-
curred in 1142 patients (27.7%) in the omecamtiv 
mecarbil group and in 1179 (28.7%) in the pla-
cebo group (hazard ratio, 0.95; 95% CI, 0.87 to 
1.03); death from any cause occurred in 1067 pa-
tients (25.9%) and 1065 patients (25.9%), respec-
tively (hazard ratio, 1.00; 95% CI, 0.92 to 1.09) 
(Table 2 and Figs. S4 and S5). The exploratory 
outcome of a first heart-failure event occurred in 
1177 patients (28.6%) in the omecamtiv mecar-
bil group and in 1236 (30.1%) in the placebo 
group (hazard ratio, 0.93; 95% CI, 0.86 to 1.00) 
(Table 2 and Fig. S6). Sensitivity analyses for 
competing risks, potentially informative data 
censoring, and missing data regarding the KCCQ 
total symptom score because of death produced 
similar results to those of the primary analyses 
(Tables S5 through S8).
Other outcomes of interest included the ef-
fects of omecamtiv mecarbil on vital signs and 
selected laboratory values (Table 3). There was 
no difference in the change in systolic blood 
pressure between baseline and 24 or 48 weeks 
between the omecamtiv mecarbil group and the 
placebo group; the heart rate was slightly lower 
in the omecamtiv mecarbil group than in the 
placebo group at the two time points. The change 
from baseline in the NT-proBNP level at week 24 
was 10% lower (95% CI, 6 to 14) in the omecam-
tiv mecarbil group than in the placebo group.
Safety
In the safety-analysis set, omecamtiv mecarbil 
was discontinued in 847 of 4110 patients (20.6%) 
and placebo in 897 of 4101 patients (21.9%). An 
adverse event was the reason for discontinuation 
in 371 patients (9.0%) in the omecamtiv mecar-
bil group and 382 (9.3%) in the placebo group. 
The trial agent was withheld because of concern 
of active myocardial infarction or ischemia in 
103 patients in the omecamtiv mecarbil group 
and in 101 patients in the placebo group.
Patients in the two groups had no change in 
potassium or creatinine levels during the course 
of the trial. The median change from baseline in 
the level of cardiac troponin I at week 24 was 4 ng 
per liter higher in the omecamtiv mecarbil group 
than that in the placebo group, according to re-
sults on the Siemens ADVIA Centaur Ultra Tropo-
nin I assay (lower limit of detection, 6 ng per liter; 
upper reference limit, 40 ng per liter).
Adjudicated major cardiac ischemic events 
occurred in 200 patients (4.9%) in the omecamtiv 
mecarbil group and in 188 (4.6%) in the placebo 
group; among these patients, myocardial infarc-
tion accounted for 122 events (3.0%) and 118 
events (2.9%), respectively (Fig. S7). Ventricular 
arrhythmic events occurred at a similar rate in 
the two groups. Additional adverse-event data are 
provided in Tables S9 and S10.
Discussion
In this randomized, placebo-controlled trial in-
volving patients with heart failure and a reduced 
ejection fraction receiving guideline-based phar-
macologic and device therapy, those in the 
omecamtiv mecarbil group had an 8% lower 
relative risk (absolute difference, 2.1 percentage 
points) of the composite primary outcome of a 
heart-failure event or death from cardiovascular 
causes than those in the placebo group. This 
effect was observed without evidence of an in-
crease in the risk of myocardial ischemic events, 
ventricular arrhythmias, or death from cardio-
vascular causes or any cause.
The modest but significant lowering of the 
incidence of the primary outcome was observed 
across a broad range of both inpatients and out-
patients,11 including those with moderate or se-
vere heart-failure symptoms and a reduced ejec-
tion fraction, systolic blood pressure, and renal 
function. The benefit was consistent across most 
subgroups, but a possible heterogeneity of effect 
was suggested by a potentially greater treatment 
effect in patients with an ejection fraction of 28% 
or less than in those with an ejection fraction of 
more than 28%. Although subgroup analyses 
have inherent limitations, potential differences 
in benefit according to ejection fraction are bio-
logically plausible, since omecamtiv mecarbil spe-
cifically increases cardiac performance.9,16 These 
findings support the hypothesis that improving 
cardiac function by selectively targeting the car-
diac sarcomere with omecamtiv mecarbil can im-
prove clinical outcomes.
This trial did not show that omecamtiv me-
carbil improved any of the secondary outcomes. 
The lack of effect on death from either cardio-
vascular causes or any cause is surprising, given 
the prior evidence with omecamtiv mecarbil of 
improvements in left ventricular volumes and 
function, as well as decreases in heart rate and 
NT-proBNP in the Chronic Oral Study of Myosin 
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Activation to Increase Contractility in Heart Fail-
ure (COSMIC-HF)9 and the reduced heart rate 
and NT-proBNP level observed in GALACTIC-HF. 
A prior meta-analysis suggested that treatments 
that reduce ventricular volumes and increase the 
ejection fraction are likely to reduce mortality.17 
Two meta-analyses of heart-failure trials showed 
no significant correlation between therapy-induced 
changes in the NT-proBNP level and mortality,18,19 
but in one of these meta-analyses, a relationship 
between a decrease in the NT-proBNP level and 
a reduction in heart-failure hospitalizations was 
observed.19 In our trial, the inpatients at the time 
of enrollment had a higher burden of symptoms 
than those enrolled as outpatients, as suggested 
by their worse KCCQ total symptom score at 
baseline. However, according to the prespecified 
testing procedure, there was no significant dif-
ference between the omecamtiv mecarbil group 
and the placebo group among either inpatients 
or outpatients.20
The identification of medicines that increase 
cardiac performance has been a goal of heart-
failure therapeutics for more than a century, yet 
the drugs that have been developed have consis-
tently increased the incidence of myocardial 
ischemia, ventricular arrhythmias, or death1,10 be-
cause of their mechanisms of increasing the mag-
nitude of intracellular calcium transients in cardio-
myocytes. As a selective cardiac myosin activator, 
omecamtiv mecarbil has no effect on these cal-
cium transients,3 and in GALACTIC-HF, the inci-
dences of myocardial ischemia, ventricular ar-
rhythmias, and death were similar in the two 
trial groups with almost 7500 patient-years of 
follow-up. These findings suggest that despite 
the small increase in plasma levels of troponin 
that have been noted in some trials8,9 and in the 
current trial, treatment with omecamtiv mecarbil 
did not increase the risk of these clinical adverse 
effects. In addition, no detrimental effects of 
omecamtiv mecarbil were detected with respect 
to blood pressure, heart rate, and creatinine or 
potassium levels.
Our trial has some limitations. It excluded 
patients over the age of 85 years and those with 
a clinically unstable condition. The underrepre-
sentation of racial groups and women in clinical 
trials is a continuing concern.21 Only 7% of the 
patients reported their race as Black, although 
the number of Black patients was larger than 
those in many previous heart-failure trials. Only 
approximately 21% of the patients were women, 
a percentage that is consistent with findings in 
other trials involving patients with heart failure 
and a reduced ejection fraction. Although the 
background therapy was generally excellent and 
more than 19% of the patients were receiving 
sacubitril–valsartan at baseline, the compelling 
results from recent trials of sodium–glucose co-
transporter 2 inhibitors22,23 were not available 
until after GALACTIC-HF had completed enroll-
ment, which limited the use of these drugs to 
only 2.6% of the patients.
Our trial showed that among patients with 
heart failure and a reduced ejection fraction, 
those who received omecamtiv mecarbil had a 
lower risk of a composite of heart-failure events 
and cardiovascular death than those who received 
placebo.
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